Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary ...

Dupixent has gained positive opinions from KOLs due to the positive data presented from the asset’s two Phase III clinical ...

Sanofi recorded 10.72 billion euros ($11.94 billion) in sales for Dupixent in 2023, which includes Regeneron's share.

With an approval based on two pivotal Phase III studies, Dupixent is now the first-ever biologic indicated for treating COPD.

Regeneron and Sanofi on Friday said the green light covers Dupixent as an add-on maintenance treatment in certain adults with uncontrolled chronic obstructive pulmonary disease, or COPD, and makes ...

Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after ...

Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following recent ...

Health-care companies ticked up, but lost ground during a generally positive week for the stock market amid fears about the implications of a tight presidential race for health-care regulation.

Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotypeFollowing recent approvals in the EU and China, the US approval is ...

After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi ...

On Friday, the FDA approved Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Dupixent (dupilumab) ...

The U.S. Food and Drug Administration approved GE HealthCare's diagnostic drug for use in detection of coronary artery ...